MeiraGTx Insider Stuart Naylor Sells Shares Amid Upcoming Drug Filings

Stuart Naylor, Chief Scientific Officer of MeiraGTx (NASDAQ:MGTX), sold 27,659 shares on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan. The sale occurred as the company approaches two drug filings and amid strong stock performance with an 89% one-year return.

By Jonathan Ponciano, The Motley Fool Sun, July 12, 2026 at 10:39 PM GMT+3 4 min read · Yahoo Finance · July 12, 2026, 19:39 UTC

MeiraGTx Insider Stuart Naylor Sells Shares Amid Upcoming Drug Filings

Tickers: $MGTX

Topics: MeiraGTx Rule 10b5-1 SEC filing stock sale

Read the full article at Yahoo Finance

More World news

Rival Technologies Index Reveals Gen Z Financial Constraints Amidst Optimistic Outlook PR Newswire · November 12, 2026, 13:42 UTC
Canadian Cybersecurity Job Postings Rise While Entry-Level Opportunities Decline PR Newswire · November 12, 2026, 13:42 UTC
Klarna Appoints Robinhood's Chris Koegel as Chief Financial Officer Seeking Alpha · November 12, 2026, 13:35 UTC
Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates Seeking Alpha · November 12, 2026, 13:37 UTC
TelyRx Holdings Appoints Co-Founder Benjamin Atkins as Interim CEO Seeking Alpha · November 12, 2026, 13:38 UTC
Nvidia shares fall following analyst downgrades and reports of potential CEO leadership changes Seeking Alpha · November 12, 2026, 13:38 UTC
Technosylva Launches Technosylva Planning Application for Multi-Hazard Utility Risk Management PR Newswire · November 12, 2026, 13:38 UTC
PVH Corp. Announces Global Workforce Reduction of Approximately 4% Seeking Alpha · November 12, 2026, 13:34 UTC
Analysis Reveals 75% of Americans Reside in Car-Dependent Areas PR Newswire · November 12, 2026, 13:38 UTC
ASML Positioned for Potential Stock Split Amid Surging AI Demand and Record Results Motley Fool · November 12, 2026, 13:31 UTC